• Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney Invest Now master your money
Moneycontrol

Home » News » Business

Feb 15, 2017, 08.27 AM | Source: CNBC-TV18

NPPA's price caps on stents may hurt manufacturers: Medanta

The National Pharmaceutical Pricing Authority’s new policy on stent is welcome as it improves access and brings in transparency, but capping coronary stent prices may hurt manufacturers, according to Medanta Chairman Naresh Trehan.

Like this story, share it with millions of investors on M3

NPPAs price caps on stents may hurt manufacturers: Medanta

The National Pharmaceutical Pricing Authority’s new policy on stent is welcome as it improves access and brings in transparency, but capping coronary stent prices may hurt manufacturers, according to Medanta Chairman Naresh Trehan.

Post Your Comments

Share Cancel

The National Pharmaceutical Pricing Authority’s new policy on stents is welcome as it improves access and brings in transparency, but capping coronary stent prices may hurt manufacturers, according to Medanta Chairman Naresh Trehan.

In a major relief to cardiac patients, the country's drug pricing regulator NPPA on Tuesday issued a notification capping coronary stent prices much below the existing prices.

A stent is a tiny expandable metal scaffold to open up narrowed or weakened arteries to ensure blood flow preventing heart attacks.

A bare metal stent on average costs about Rs 10,000-20,000, while a drug eluting stent (DES) ranges between Rs 25,000-80,000. NPPA has now capped the prices of bare metal stent at Rs 7,260 and drug eluting stent (DES) and biodegradable stents at Rs 29,600. Both the prices are exclusive of value added tax.

DES constitutes 95 percent of the market. NPPA has asked all the manufacturers selling stents at prices higher than the ceiling price to cut the price in compliance with the notification.

Trehan said the NPPA policy doesn’t address issues such as pricing of special stents and those in inventory. He asserted that the policy must consider flexible pricing for new technology stents.

Watch video for more…

Buy, Hold, Sell ? Hear it first on M3
NPPAs price caps on stents may hurt manufacturers: Medanta

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login